FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165581900> ?p ?o ?g. }

• W3165581900 endingPage "1145" @default.
• W3165581900 startingPage "1145.1" @default.
• W3165581900 abstract "Background: There are no RA response predictors for our patients. The decision to initiate a first biological depends on multiple factors such as rheumatologist experience, clinical characteristics of the patient and health system. What is clear is that the best strategy is T2T. Objectives: To know the clinical characteristics and persistence of the first biological DMARD in patients receiving bDMARDS TNF inhibitors vs DMARDs aimed at other targets. Methods: A observational cohort of adult RA patients (ACR/EULAR 2010) in a rheumatology department of a third-level university hospital. All patients were treated with a first bDMARD marketed in Spain, from 2010 to December 2020 and prescribed according to product data sheet. Biological drugs were divided into TNF inhibitors drugs (adalimumab, etanercept, infliximab, golimumab, certolizumab) and Other targets (abatacept, rituximab, sarilumab, tocilizumab). Clinical data, duration of treatment and EULAR response were collected from each patient. The data were analyzed with descriptive, bivariate statistics and survival analysis adjusted for age, sex, FR, erosions and duration of the disease. Results: Data were collected from 332 patients (table 1). Patients treated with other target bDMARDs were mostly female, with higher activity, shorter disease duration, and treated without MTX.b Survival graphs showed that regardless of the target chosen as fist bDMARD, EULAR response rates and persistence to the drug were similar. Table 1. Variable TNF inhibitors n=194 Other targets n = 138 Total n =332 p n (%) n (%) n (%) 0.02 Female 142 (73) 115 (83) 257 (77) 0.2 FR + 163 (82) 121 (88) 284 (86) 0.6 ACPA + 125 (63) 84 (61) 209 (63) 0.9 Erosions 177 (89) 80 (58) 257 (77) 0.01 Concomitant MTX 153 (77) 62 (47) 215 (65) 0.003 EULAR response Good 103 (77) 67 (71) 170 (75) 0.2 Moderate 24 (18) 16 (17) 40 (17) No 7 (5) 11 (11) 18 (8) Mean ± SD Mean ± SD Mean ± SD Age (years) 55.7 ± 13.3 57.6 ± 11.9 56.5 ± 12.7 0.1 Evolution of RA (years) 9.6 ± 10.2 7.5 ± 7.5 8.7 ± 9.2 0.04 Persistence (months) 19.3 ± 20.5 16.07 ± 15.11 17.5 ± 18.5 0.04 DAS28VSG4V basal 5.02 ± 1.5 5.59 ± 1.03 5.25 ± 1.3 0.001 DAS28VSG4V final 2.68 ± 1.1 2.84 ± 1.4 2.7 ± 1.25 0,31 Conclusion: Patients receiving Anti-TNF vs bDMARD with other mechanisms of action have clinical differences. However, the response and persistence to the drug are similar, perhaps due to the implementation of the correct T2T strategy. Disclosure of Interests: None declared" @default.
• W3165581900 created "2021-06-07" @default.
• W3165581900 creator A5005698160 @default.
• W3165581900 creator A5032445443 @default.
• W3165581900 creator A5032667784 @default.
• W3165581900 creator A5034955577 @default.
• W3165581900 creator A5041114851 @default.
• W3165581900 creator A5063377639 @default.
• W3165581900 creator A5081775752 @default.
• W3165581900 creator A5089631749 @default.
• W3165581900 creator A5090009812 @default.
• W3165581900 date "2021-05-19" @default.
• W3165581900 modified "2023-10-14" @default.
• W3165581900 title "AB0239 PERSISTENCE TO BIOLOGICAL DMARDS TNF INHIBITORS VS BIOLOGICAL DMARDS NO TNF INHIBITORS AFTER FAILURE TO SYNTHETIC CONVENTIONAL DMARDS IN RA PATIENTS TREATED IN STANDARD CLINICAL PRACTICE" @default.
• W3165581900 doi "https://doi.org/10.1136/annrheumdis-2021-eular.3920" @default.
• W3165581900 hasPublicationYear "2021" @default.
• W3165581900 type Work @default.
• W3165581900 sameAs 3165581900 @default.
• W3165581900 citedByCount "0" @default.
• W3165581900 crossrefType "journal-article" @default.
• W3165581900 hasAuthorship W3165581900A5005698160 @default.
• W3165581900 hasAuthorship W3165581900A5032445443 @default.
• W3165581900 hasAuthorship W3165581900A5032667784 @default.
• W3165581900 hasAuthorship W3165581900A5034955577 @default.
• W3165581900 hasAuthorship W3165581900A5041114851 @default.
• W3165581900 hasAuthorship W3165581900A5063377639 @default.
• W3165581900 hasAuthorship W3165581900A5081775752 @default.
• W3165581900 hasAuthorship W3165581900A5089631749 @default.
• W3165581900 hasAuthorship W3165581900A5090009812 @default.
• W3165581900 hasBestOaLocation W31655819001 @default.
• W3165581900 hasConcept C126322002 @default.
• W3165581900 hasConcept C1862650 @default.
• W3165581900 hasConcept C198451711 @default.
• W3165581900 hasConcept C2776215756 @default.
• W3165581900 hasConcept C2777138892 @default.
• W3165581900 hasConcept C2777178219 @default.
• W3165581900 hasConcept C2777226972 @default.
• W3165581900 hasConcept C2777575956 @default.
• W3165581900 hasConcept C2779134260 @default.
• W3165581900 hasConcept C2779338263 @default.
• W3165581900 hasConcept C2779605438 @default.
• W3165581900 hasConcept C2779722408 @default.
• W3165581900 hasConcept C2780132546 @default.
• W3165581900 hasConcept C2780653079 @default.
• W3165581900 hasConcept C2781290027 @default.
• W3165581900 hasConcept C71924100 @default.
• W3165581900 hasConcept C72563966 @default.
• W3165581900 hasConceptScore W3165581900C126322002 @default.
• W3165581900 hasConceptScore W3165581900C1862650 @default.
• W3165581900 hasConceptScore W3165581900C198451711 @default.
• W3165581900 hasConceptScore W3165581900C2776215756 @default.
• W3165581900 hasConceptScore W3165581900C2777138892 @default.
• W3165581900 hasConceptScore W3165581900C2777178219 @default.
• W3165581900 hasConceptScore W3165581900C2777226972 @default.
• W3165581900 hasConceptScore W3165581900C2777575956 @default.
• W3165581900 hasConceptScore W3165581900C2779134260 @default.
• W3165581900 hasConceptScore W3165581900C2779338263 @default.
• W3165581900 hasConceptScore W3165581900C2779605438 @default.
• W3165581900 hasConceptScore W3165581900C2779722408 @default.
• W3165581900 hasConceptScore W3165581900C2780132546 @default.
• W3165581900 hasConceptScore W3165581900C2780653079 @default.
• W3165581900 hasConceptScore W3165581900C2781290027 @default.
• W3165581900 hasConceptScore W3165581900C71924100 @default.
• W3165581900 hasConceptScore W3165581900C72563966 @default.
• W3165581900 hasIssue "Suppl 1" @default.
• W3165581900 hasLocation W31655819001 @default.
• W3165581900 hasOpenAccess W3165581900 @default.
• W3165581900 hasPrimaryLocation W31655819001 @default.
• W3165581900 hasRelatedWork W2026720490 @default.
• W3165581900 hasRelatedWork W2075390633 @default.
• W3165581900 hasRelatedWork W2119512053 @default.
• W3165581900 hasRelatedWork W2139415330 @default.
• W3165581900 hasRelatedWork W2143724376 @default.
• W3165581900 hasRelatedWork W2314759778 @default.
• W3165581900 hasRelatedWork W2315852881 @default.
• W3165581900 hasRelatedWork W2329967385 @default.
• W3165581900 hasRelatedWork W2734364973 @default.
• W3165581900 hasRelatedWork W3033741069 @default.
• W3165581900 hasVolume "80" @default.
• W3165581900 isParatext "false" @default.
• W3165581900 isRetracted "false" @default.
• W3165581900 magId "3165581900" @default.
• W3165581900 workType "article" @default.